Based on 11 Wall Street analysts offering 12 month price targets for Xenon in the last 3 months. The average price target is €55.13 with a high forecast of €59.06 and a low forecast of €47.81. The average price target represents a 46.61% change from the last price of €37.60.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"€30","45":"€45","60":"€60","37.5":"€37.5","52.5":"€52.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":59.062752,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">€59.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55.1252352,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">€55.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47.812704,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">€47.81</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,37.5,45,52.5,60],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2023","6":"Oct<br/>2023","9":"Jan<br/>2024","12":"Apr<br/>2024","25":"Apr<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39,40.54328861538462,42.08657723076923,43.62986584615385,45.17315446153846,46.71644307692308,48.259731692307696,49.80302030769231,51.346308923076926,52.889597538461544,54.432886153846155,55.976174769230774,57.51946338461539,{"y":59.062752,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39,40.240402707692304,41.480805415384616,42.72120812307692,43.96161083076923,45.202013538461536,46.44241624615385,47.68281895384615,48.92322166153846,50.16362436923077,51.40402707692308,52.64442978461538,53.884832492307694,{"y":55.1252352,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39,39.677900307692305,40.35580061538462,41.03370092307692,41.71160123076923,42.38950153846154,43.06740184615384,43.745302153846154,44.42320246153846,45.101102769230764,45.779003076923075,46.45690338461538,47.13480369230769,{"y":47.812704,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":32.6,"date":1681430400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.6,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.8,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.6,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.4,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.8,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.2,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.4,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.8,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€59.06

Average Price Target€55.13

Lowest Price Target€47.81

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

xxxxxxxxxxxxxxxxxx

Needham

xxxxxxxxxxxxx

Reiterated

04/12/24

xxxxxxxxxxxxxxxxxx

Guggenheim

xxxxxxxxxxxxx

Reiterated

03/04/24

xxxxxxxxxxxxxxxxxx

Goldman Sachs

xxxxxxxxxxxxx

Reiterated

03/01/24

xxxxxxxxxxxxxxxxxx

Stifel Nicolaus

xxxxxxxxxxxxx

Reiterated

03/01/24

xxxxxxxxxxxxxxxxxx

Wedbush

xxxxxxxxxxxxx

Reiterated

03/01/24

xxxxxxxxxxxxxxxxxx

Robert W. Baird

xxxxxxxxxxxxx

Reiterated

03/01/24

xxxxxxxxxxxxxxxxxx

TD Cowen

xxxxxxxxxxxxx

Assigned

03/01/24

xxxxxxxxxxxxxxxxxx

Citi

xxxxxxxxxxxxx

Reiterated

03/01/24

xxxxxxxxxxxxxxxxxx

RBC Capital

xxxxxxxxxxxxx

Reiterated

02/29/24

xxxxxxxxxxxxxxxxxx

Wells Fargo

xxxxxxxxxxxxx

Reiterated

02/29/24

Jason Gerberry

Bank of America Securities

€52.50

Buy

39.63%

Upside

Reiterated

02/29/24

Analysts' Opinions Are Mixed on These Healthcare Stocks: Amicus (NASDAQ: FOLD), Xenon (NASDAQ: XENE) and Veeva Systems (NYSE: VEEV)

Tessa Romero

J.P. Morgan

€55.31

Buy

47.11%

Upside

Reiterated

12/19/23

Analysts Offer Insights on Healthcare Companies: Xenon (NASDAQ: XENE) and Alphatec Holdings (NASDAQ: ATEC)

Andrew Tsai

Jefferies

€56.25

Buy

49.60%

Upside

Reiterated

12/15/23

Xenon's Stock Rated Buy on Promising MDD and Epilepsy Drug Potential

Marc Goodman

Leerink Partners

―

Buy

―

Reiterated

11/27/23

Wall Street Analysts Are Bullish on Top Healthcare Picks

Charles Duncan

Cantor Fitzgerald

―

Buy

―

Initiated

10/23/23

Xenon Pharmaceuticals assumed with an Overweight at Cantor FitzgeraldXenon Pharmaceuticals assumed with an Overweight at Cantor Fitzgerald

Best Analysts Covering Xenon

Which Analyst Should I Follow If I Want to Buy DE:XP0 and Sell After:

1 Month

Andrew TsaiJefferies

Success Rate

7/11 ratings generated profit

Average Return

+2.09%

reiterated a buy rating 4 months ago

Copying Andrew Tsai's trades and holding each position for 1 Month would result in 63.64% of your transactions generating a profit, with an average return of +2.09% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

3 Months

No data currently available

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

1 Year

No data currently available

2 Years

No data currently available

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

XP0 Analyst Recommendation Trends

Rating

Dec 23

Jan 24

Feb 24

Mar 24

Apr 24

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, XP0 has received 13 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. XP0 average Analyst price target in the past 3 months is €55.13.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxxxxxxxxxxxxxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

XP0 Financial Forecast

XP0 Earnings Forecast

Next quarter’s earnings estimate for XP0 is -€0.63 with a range of -€0.73 to -€0.53. The previous quarter’s EPS was -€0.60. XP0 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.49% of the time in the same period. In the last calendar year XP0 has Underperformed its overall industry.

XP0 Sales Forecast

Next quarter’s sales forecast for XP0 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. XP0 beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 59.70% of the time in the same period. In the last calendar year XP0 has Underperformed its overall industry.

XP0 Stock Forecast FAQ

What is DE:XP0’s average 12-month price target, according to analysts?

Based on analyst ratings, Xenon’s 12-month average price target is €55.13.

What is DE:XP0’s upside potential, based on the analysts’ average price target?

Xenon has 46.61% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Xenon a Buy, Sell or Hold?

Xenon has a conensus rating of Strong Buy, which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.

What is Xenon’s share price target?

The average share price target for Xenon is €55.13. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €59.06 ,and the lowest forecast is €47.81. The average share price target represents 46.61% Increase from the current price of €37.6.

What do analysts say about Xenon?

Xenon’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of Xenon?

To buy shares of DE:XP0, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Xenon (XP0) Stock Forecast & Price Target

XP0 Analyst Ratings

XP0 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Xenon

XP0 Analyst Recommendation Trends

XP0 Financial Forecast

XP0 Earnings Forecast

XP0 Sales Forecast

XP0 Stock Forecast FAQ

Get More with TipRanks Premium

Detailed List of Analyst Forecasts